What is new about this FDA approval?

The FDA approved a subcutaneous starter dose of Leqembi given weekly via an autoinjector at home, replacing biweekly IV infusions.

Which patients are eligible for this treatment?

Patients with early Alzheimer's disease (mild cognitive impairment or mild dementia) with confirmed amyloid pathology.

When will subcutaneous Leqembi be available?

Biogen has not yet announced availability, but details are expected soon.

FDA Approves Biogen's Subcutaneous Leqembi Starter Dose

Biogen received FDA approval for a subcutaneous starter dose of Leqembi (Iqlik), allowing early Alzheimer's patients to begin treatment with a weekly at-home autoinjector instead of biweekly IV infusions.

July 14, 2026

2 min read

Source: Zacks

Biogen (BIIB) has secured FDA approval for the subcutaneous starter dose of its Alzheimer's drug Leqembi (Iqlik), the company announced. This approval enables patients with early Alzheimer's disease to initiate treatment using a weekly at-home autoinjector, replacing the previous biweekly hour-long intravenous infusions.

The Product

Leqembi (lecanemab) is a disease-modifying therapy that targets amyloid plaques in the brain. The new subcutaneous formulation (Iqlik) offers greater convenience for patients and caregivers, allowing administration at home without clinic visits.

Pricing and Availability

Biogen has not yet disclosed pricing or commercial launch timelines for the new formulation. Details are expected to be announced soon.

Competition

Leqembi competes with other anti-amyloid drugs such as Aduhelm (also from Biogen) and Eli Lilly's (LLY) donanemab. The ease of subcutaneous administration could provide a competitive edge.

Potential Impact on the Company

Improved convenience is likely to boost adoption among patients and physicians, potentially increasing Biogen's revenue in the growing Alzheimer's treatment market.

Frequently Asked Questions

Leqembi (lecanemab) is a disease-modifying Alzheimer's drug that removes amyloid plaques from the brain.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.